ExodusPoint Capital Management’s Design Therapeutics DSGN Stock Holding History

ExodusPoint Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$597K	Buy	+41,286	New	+$515K	﹤0.01%	1189
2023 Q3	–	Sell	-265,384	Closed	-$1.67M	–	1794
2023 Q2	$1.67M	Buy	265,384 +109,246	+70%	+$669K	0.01%	884
2023 Q1	$901K	Buy	156,138 +105,407	+208%	+$788K	0.01%	1175
2022 Q4	$521K	Sell	50,731 -1,110	-2%	-$15K	0.01%	1158
2022 Q3	$867K	Buy	+51,841	New	+$1.03M	0.01%	1164

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ExodusPoint Capital Management's DSGN Position: Q2 2026 in Review

ExodusPoint Capital Management opened a new position in Design Therapeutics (DSGN) in Q2 2026: 41,286 shares worth $597K. The stake represents ﹤0.01% of the portfolio and ranks #1189 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in DSGN as recently as Q2 2023.

ExodusPoint Capital Management first reported a position in DSGN in Q3 2022 and has held it in 5 quarters since. The position peaked at $1.67M in Q2 2023. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

ExodusPoint Capital Management held 41,286 shares of Design Therapeutics worth $597K as of Q2 2026.
Design Therapeutics was a new ExodusPoint Capital Management position in Q2 2026.
Design Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q2 2026, its #1189 holding.
ExodusPoint Capital Management first reported a position in Design Therapeutics in Q3 2022 and has held it in 5 quarters since.
ExodusPoint Capital Management's Design Therapeutics position peaked at $1.67M in Q2 2023.
136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.